122 related articles for article (PubMed ID: 38490856)
1. Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial.
Möller F; Månsson M; Wallström J; Hellström M; Hugosson J; Arnsrud Godtman R
Eur Urol; 2024 Mar; ():. PubMed ID: 38490856
[TBL] [Abstract][Full Text] [Related]
2. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
Boschheidgen M; Albers P; Schlemmer HP; Hellms S; Bonekamp D; Sauter A; Hadaschik B; Krilaviciute A; Radtke JP; Seibold P; Lakes J; Arsov C; Gschwend JE; Herkommer K; Makowski M; Kuczyk MA; Wacker F; Harke N; Debus J; Körber SA; Benner A; Kristiansen G; Giesel FL; Antoch G; Kaaks R; Becker N; Schimmöller L
Eur Urol; 2024 Feb; 85(2):105-111. PubMed ID: 37863727
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial.
Wallström J; Geterud K; Kohestani K; Maier SE; Pihl CG; Socratous A; Stranne J; Arnsrud-Godtman R; Månsson M; Hellström M; Hugosson J
Eur Urol Oncol; 2022 Feb; 5(1):54-60. PubMed ID: 34580053
[TBL] [Abstract][Full Text] [Related]
5. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
[TBL] [Abstract][Full Text] [Related]
6. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
[TBL] [Abstract][Full Text] [Related]
7. The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the Göteborg-1 Prostate Cancer Screening Trial.
Godtman RA; Kollberg KS; Pihl CG; Månsson M; Hugosson J
Eur Urol; 2022 Sep; 82(3):311-317. PubMed ID: 35120773
[TBL] [Abstract][Full Text] [Related]
8. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population.
Fredsøe J; Sandahl M; Vedsted P; Jensen JB; Ulhøi BP; Borre M; Sørensen KD; Pedersen BG;
Eur Urol Oncol; 2023 Oct; 6(5):484-492. PubMed ID: 37537016
[TBL] [Abstract][Full Text] [Related]
9. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial.
Josefsson A; Månsson M; Kohestani K; Spyratou V; Wallström J; Hellström M; Lilja H; Vickers A; Carlsson SV; Godtman R; Hugosson J
Eur Urol; 2024 May; ():. PubMed ID: 38772787
[TBL] [Abstract][Full Text] [Related]
10. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
11. An Evaluation of Screening Pathways Using a Combination of Magnetic Resonance Imaging and Prostate-specific Antigen: Results from the IP1-PROSTAGRAM Study.
Eldred-Evans D; Tam H; Sokhi H; Padhani AR; Connor M; Price D; Gammon M; Klimowska-Nassar N; Burak P; Day E; Winkler M; Fiorentino F; Ahmed HU
Eur Urol Oncol; 2023 Jun; 6(3):295-302. PubMed ID: 37080821
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
13. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
[TBL] [Abstract][Full Text] [Related]
14. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
[TBL] [Abstract][Full Text] [Related]
15. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
16. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial.
Carlsson SV; Arnsrud Godtman R; Pihl CG; Vickers A; Lilja H; Hugosson J; Månsson M
Eur Urol; 2023 Feb; 83(2):103-109. PubMed ID: 36334968
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.
Frånlund M; Arnsrud Godtman R; Carlsson SV; Lilja H; Månsson M; Stranne J; Hugosson J
Scand J Urol; 2018 Aug; 52(4):256-262. PubMed ID: 30241447
[TBL] [Abstract][Full Text] [Related]
18. Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study.
Rannikko A; Leht M; Mirtti T; Kenttämies A; Tolonen T; Rinta-Kiikka I; Kilpeläinen TP; Natunen K; Lilja H; Lehtimäki T; Raitanen J; Kujala P; Ronkainen J; Matikainen M; Petas A; Taari K; Tammela T; Auvinen A
BJU Int; 2022 Aug; 130(2):193-199. PubMed ID: 34958531
[TBL] [Abstract][Full Text] [Related]
19. Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING).
Wetterauer C; Matthias M; Pueschel H; Deckart A; Bubendorf L; Mortezavi A; Arbelaez E; Jean Winkel D; Heye T; Boll DT; Merkle E; Hayoz S; Seifert HH; Rentsch CA
Eur Urol Focus; 2024 Feb; ():. PubMed ID: 38402105
[TBL] [Abstract][Full Text] [Related]
20. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]